Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 1, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 11, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 18, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, Calif., and VANCOUVER, Canada, April 12, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 13, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study Phase 1b ...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 2, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA, Dec. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Oct. 31, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Oct. 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 4, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 2, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant...
South San Francisco, California and Vancouver, Canada, March 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 9, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a...
First presentation of preclinical data for ESSA's androgen receptor (AR) N-terminal domain degraders ANITen bAsed Chimera (ANITAC™) degraders degrade ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.